𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Resistance of ex vivo expanded CD3+CD56+T cells to Fas-mediated apoptosis

✍ Scribed by Michael R. Verneris; Martin Kornacker; Volker Mailänder; Robert S. Negrin

Publisher
Springer-Verlag
Year
2000
Tongue
English
Weight
434 KB
Volume
49
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Frequency and resistance of CD95 (Fas/Ap
Frequency and resistance of CD95 (Fas/Apo-1) gene-transfected tumor cells to CD95-mediated apoptosis by the elimination and methylation of integrated DNA
✍ Motomu Shimizu; Takayuki Yoshimoto; Mayumi Sato; Akio Matsuzawa; Yasutaka Takeda 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 598 KB

## Abstract It is important for more effective gene therapies to clarify the mechanisms by which cDNA integrated into cells can maintain or lose its function __in vivo__. We evaluated genetic and epigenetic events leading to alternation of the introduced CD95 (Fas/Apo‐1) gene as a model of gene the

Treatment of the P815 murine mastocytoma
Treatment of the P815 murine mastocytoma with cisplatin or etoposide up-regulates cell-surface Fas (CD95) expression and increases sensitivity to anti-Fas antibody-mediated cytotoxicity and to lysis by anti-CD3-activated killer-T cells
✍ Brent A. Williams; Andrew P. Makrigiannis; Jonathan Blay; David W. Hoskin 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 122 KB 👁 2 views

We have investigated the effect of pre-treatment with the anti-cancer drugs cisplatin and etoposide on the susceptibility of P815 murine mastocytoma cells to lysis by murine spleen-derived anti-CD3-activated killer-T (AK-T) cells. A 20 hr pre-treatment with cisplatin (0.2-2 microg/ml) or etoposide (